Loading patent…
AssigneeBayer Aktiengesellschaft
InventorsMaik Stefan Wilhelm OBENDORF, Frank SACHER, Jörg MÜLLER, Ralf LESCHE, Christian VOTSMEIER, Stephan MÄRSCH, Jan TEBBE, Philipp ELLINGER, Patrick Michael SMITH, Jenny FITTING, Katharina FILARSKY, Mathias GEHRMANN, Marcus KARLSTETTER, Ernst WEBER, Mark TRAUTWEIN
Estimating the term…
The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding, prolonged bleeding, altered bleeding pattern, dysmenorrhea, as well as of the underlying diseases leiomyoma and endometriosis and the use of the agent to inhibit menstruation. Furthermore, the invention provides novel IL-11 antibodies.
An isolated antibody or antigen-binding fragment thereof capable of binding to IL-11 and inhibiting IL-11 mediated signaling, wherein said isolated antibody or antigen-binding fragment thereof is capable of reducing blood loss during abnormal uterine bleeding.
(canceled)
-36. (canceled)
Dependencies are inferred from the claim text.